Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Radiographics ; 39(5): 1549-1568, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31498746

RESUMEN

Transvaginal sonography (TVS) is a valuable primary imaging tool for the initial evaluation and management of endometriosis, a complex multifocal disease process with a varied spectrum of clinical and morphologic features that can substantially affect quality of life. The high accuracy of TVS for the detailed mapping of disease extent, an essential process for guiding treatment strategies, is well documented. The dynamic nature of US provides added value, revealing information that is not easily addressed with other imaging modalities. As recognized by the International Deep Endometriosis Analysis Consensus Group, a dedicated standardized protocol that is used by experienced and knowledgeable operators is necessary for a complete evaluation. The four components of a dedicated TVS protocol for evaluation of pelvic endometriosis are (a) evaluation of the uterus and adnexa, (b) dedicated search for deep infiltrating endometriosis, (c) assessment of the sliding sign, and (d) detection of sonographic soft markers. These components are described, and the multiple locations and US findings of endometriosis within the pelvis are reviewed, with emphasis on the unique features of US as an extension of the physical examination. In addition to enabling evaluation of the static findings of adenomyosis, endometrioma, hydrosalpinx, hematosalpinx, and hypoechoic nodules of deep infiltrating endometriosis, dynamic TVS enables assessment of pouch of Douglas obliteration, organ mobility, and site-specific tenderness, as well as tenderness-guided imaging. The benefits of implementing a dedicated TVS protocol in terms of improved patient care are also discussed. Online supplemental material is available for this article. ©RSNA, 2019.


Asunto(s)
Endometriosis/diagnóstico por imagen , Ultrasonografía/métodos , Medios de Contraste , Femenino , Humanos , Vagina
2.
Int J Clin Oncol ; 17(4): 380-4, 2012 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-21823041
3.
Exp Clin Transplant ; 20(11): 1000-1008, 2022 11.
Artículo en Inglés | MEDLINE | ID: mdl-36524886

RESUMEN

OBJECTIVES: Chronic liver disease is often associated with testosterone deficiency. However, testosterone replacement does not improve hepatic function or survival with diseased liver. So far, to our knowledge, testosterone replacement therapy after successful livertransplantforfunctional sarcopenia has not been studied. We had 3 goals: (1) define postoperative functional sarcopenia afterlivertransplant with serum testosterone level; (2) examine the role of short-term testosterone replacement therapy with active in-bed exercise of upper and lower extremity joints; and (3) correlate functional sarcopenia with skeletal muscle index and skeletal muscle density in relation to ascites, pleural effusion subtracted body mass index. MATERIALS AND METHODS: We evaluated 16 liver transplant recipients who had been receiving posttransplanttestosterone replacementtherapy with functional sarcopenia. Preoperative and postoperative demographics and laboratory and radiological data were retrieved; body mass index, skeletal muscle index, and skeletal muscle density were calculated. For this retrospective study, institutional review board approval was obtained before the electronic database was reviewed and analyzed. RESULTS: Mean testosterone level was 28.3 ng/dL (<5% of expected). Twelve patients received 1 dose, and the remaining 4 patients received >1 dose oftestosterone cypionate, 200 mg. Mean hospital stay was 26 days. Seven patients were discharged home, with the remaining patients to a rehabilitation facility or nursing home. One patient died from a cardiac event, and another patient died from recurrent metastatic malignancy. The 1-year and 5-year actuarial patient and graft survival rates were 93.8% and 87.5%, respectively. Overall, 5 patients were sarcopenic by skeletal muscle index, and 6 patients had poor muscle quality by skeletal muscle density. CONCLUSIONS: Testosterone deficiency after liver transplant exists with functional sarcopenia. Two- thirds of such recipients have low skeletal muscle index and/or have low skeletal muscle density. Short- term testosterone replacement therapy with in-bed active exercise provides 5-year patient and graft survival of 87.5%.


Asunto(s)
Hepatopatías , Trasplante de Hígado , Sarcopenia , Humanos , Sarcopenia/diagnóstico por imagen , Sarcopenia/etiología , Trasplante de Hígado/efectos adversos , Estudios Retrospectivos , Resultado del Tratamiento , Recurrencia Local de Neoplasia/etiología , Recurrencia Local de Neoplasia/patología , Hepatopatías/patología , Músculo Esquelético , Testosterona/efectos adversos
4.
Am Surg ; 86(2): 90-94, 2020 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-32167041

RESUMEN

We aimed to evaluate the surgical margin outcomes and re-excision rates in patients undergoing bracketed seed localization of biopsy-proven breast cancer detected on screening mammogram. After approval by our Institutional Review Board, we retrospectively identified patients who had undergone iodine-125 seed localized lumpectomy at our institution from January 2010 to June 2017 by one of two fellowship-trained breast surgeons. Of those patients, a subset of 25 patients were identified who had undergone bracketed seed localization, defined as two or more seeds used to delineate the radiographic borders of the area of concern. All patients had originally presented with calcifications identified on screening mammogram that were subsequently diagnosed as ductal carcinoma in situ and/or invasive ductal carcinoma by image-guided biopsy performed at our institution. Eight patients had one positive margin on final surgical pathology and required re-excision (32%). One patient was converted to mastectomy. Of the patients requiring re-excision, the average maximum linear extent of calcifications was 3.4 cm (SD 0.97), whereas it was 3.1 cm (SD 1.2) in patients with negative surgical margins (P = 0.5). Bracketing calcifications with radioactive seeds can potentially allow more patients to undergo breast conservation surgery.


Asunto(s)
Neoplasias de la Mama/cirugía , Carcinoma Ductal de Mama/cirugía , Carcinoma Intraductal no Infiltrante/cirugía , Radioisótopos de Yodo/administración & dosificación , Mastectomía Segmentaria/métodos , Tratamientos Conservadores del Órgano/métodos , Neoplasias de la Mama/diagnóstico por imagen , Calcinosis/diagnóstico por imagen , Carcinoma Ductal de Mama/diagnóstico por imagen , Carcinoma Intraductal no Infiltrante/diagnóstico por imagen , Femenino , Marcadores Fiduciales , Humanos , Biopsia Guiada por Imagen , Mamografía , Márgenes de Escisión , Reoperación/estadística & datos numéricos , Estudios Retrospectivos
5.
Biomedicines ; 6(2)2018 Apr 17.
Artículo en Inglés | MEDLINE | ID: mdl-29673151

RESUMEN

Hepatocellular carcinoma (HCC) is increasing in incidence, and the associated mortality rate remains among the highest. For advanced HCC, sorafenib has been shown to slightly prolong survival, and regorafenib and nivolumab, both recently approved by the United States Food and Drug Administration (FDA), may produce clinical benefits to a limited extent. Systemic chemotherapy has been shown to produce a modest response, but there is no clinically valid biomarker that can be used to predict which patients may benefit. In this case study, we present two patients with metastatic HCC, they received systemic treatment using capecitabine, oxaliplatin, and either bevacizumab or sorafenib. The tumor response to treatment was determined by the progression-free survival (PFS). Molecular profiling of the tumors showed differential expression of biochemical markers and different mutational status of the TP53 and β-catenin (CTNNB1) genes. We hypothesize that the PFS correlates with the tumor molecular profiles, which may be predictive of the therapeutic response to systemic chemotherapy. Further investigation is indicated to correlate tumor biomarkers and treatment responses, with the objective of personalizing the therapies for patients with advanced HCC.

7.
Ultrasound Q ; 28(2): 105-24, 2012 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-22572863

RESUMEN

Routine use of ultrasound (US) in antenatal screening has increased over the past decade among both low- and high-risk pregnancies. Recognition of common US imaging pitfalls and artifacts associated with frequently encountered fetal anomalies on obstetric US is imperative to avoid misdiagnosis. The purpose of this article is to present practical tips on how to accurately diagnose 6 fetal anomalies including choroid plexus cyst, mild ventriculomegaly, echogenic intracardiac focus, prominent thymus, mild renal pelviectasis, and echogenic bowel. A suspected fetal anomaly should always be visualized in the correct plane and confirmed in at least one other plane. If the abnormal finding persists, performance of precise measurements in the relevant planes using appropriate gain settings, color Doppler imaging, and the application of specific criteria is necessary to achieve the correct diagnosis and to recommend appropriate patient referral.


Asunto(s)
Artefactos , Enfermedades Fetales/diagnóstico por imagen , Aumento de la Imagen/métodos , Ultrasonografía Prenatal/métodos , Humanos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA